353 related articles for article (PubMed ID: 35792393)
1. Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies.
Latifi-Pupovci H
Biomed Pharmacother; 2022 Sep; 153():113368. PubMed ID: 35792393
[TBL] [Abstract][Full Text] [Related]
2. The novel zoonotic COVID-19 pandemic: An expected global health concern.
Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
[TBL] [Abstract][Full Text] [Related]
3. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
4. Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches.
Ahmadi S; Bazargan M; Elahi R; Esmaeilzadeh A
Mol Immunol; 2023 Apr; 156():10-19. PubMed ID: 36857806
[TBL] [Abstract][Full Text] [Related]
5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
6. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
7. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
Znaidia M; Demeret C; van der Werf S; Komarova AV
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
[TBL] [Abstract][Full Text] [Related]
9. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
Prompetchara E; Ketloy C; Palaga T
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):1-9. PubMed ID: 32105090
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.
Low ZY; Zabidi NZ; Yip AJW; Puniyamurti A; Chow VTK; Lal SK
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146796
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways.
Oh SJ; Shin OS
J Microbiol; 2022 Mar; 60(3):290-299. PubMed ID: 35122601
[TBL] [Abstract][Full Text] [Related]
12. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
Borges RC; Hohmann MS; Borghi SM
Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
[TBL] [Abstract][Full Text] [Related]
14. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
Bouayad A
Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
[TBL] [Abstract][Full Text] [Related]
15. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Noor R
Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
[TBL] [Abstract][Full Text] [Related]
16. The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity.
Gu W; Gan H; Ma Y; Xu L; Cheng ZJ; Li B; Zhang X; Jiang W; Sun J; Sun B; Hao C
Virol J; 2022 Mar; 19(1):49. PubMed ID: 35305698
[TBL] [Abstract][Full Text] [Related]
17. Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach.
Das A; Roy S; Swarnakar S; Chatterjee N
Clin Immunol; 2021 Oct; 231():108804. PubMed ID: 34303849
[TBL] [Abstract][Full Text] [Related]
18. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
[TBL] [Abstract][Full Text] [Related]
19. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
[TBL] [Abstract][Full Text] [Related]
20. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
